Allurion Technologies, Inc.
ALUR Healthcare Medical Devices
Allurion Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $15.2 million, down 52.6% from fiscal 2024. In the quarter to March 2026, revenue fell 47.2%, EPS fell 46.5% and free cash flow grew 66.0%, each against the same quarter a year earlier.
Follow ALUR
Allurion Technologies, Inc. (ALUR) EV/Sales
As of 15 October 2026, Allurion Technologies, Inc. (ALUR) trades at a EV/Sales of 5.3×. Over the past ten years it has ranged from 0.0× (March 2023) to 5.8× (June 2026); the current reading is higher than 90% of that period. That is above the Medical Devices industry median of 2.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 4.4× | 129.89% |
| FY2024 | 1.9× | 251.16% |
| FY2023 | 0.5× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 5.3× | 21.52% |
| Dec 2025 | 4.4× | 13.47% |
| Sep 2025 | 3.8× | 36.21% |
| Jun 2025 | 2.8× | 58.02% |
| 12 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RBOT Vicarious Surgical Inc. compare | n/m |
| MODD Modular Medical, Inc. compare | n/m |
| BDMD Baird Medical Investment Holdings Limited compare | n/m |
| IRIX IRIDEX Corporation compare | 0.3× |
| ARAY Accuray Incorporated compare | 0.3× |
| LFWD Lifeward Ltd. compare | 0.9× |
| ALUR Allurion Technologies, Inc. | 5.3× |
| PAVM PAVmed Inc. compare | 236× |
| HSCS HeartSciences Inc. compare | 556× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)